BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 29720506)

  • 1. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer.
    Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y
    Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506
    [No Abstract]   [Full Text] [Related]  

  • 2. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
    Hung SI; Chu MT; Hou MM; Lee YS; Yang CK; Chu SY; Liu FY; Hsu HC; Pao SC; Teng YC; Chen CB; Chao A; Chung WH; Chang JW; Lai CH
    Biomed Pharmacother; 2023 Dec; 169():115928. PubMed ID: 38011788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
    Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
    Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
    Anderson KG; Voillet V; Bates BM; Chiu EY; Burnett MG; Garcia NM; Oda SK; Morse CB; Stromnes IM; Drescher CW; Gottardo R; Greenberg PD
    Cancer Immunol Res; 2019 Sep; 7(9):1412-1425. PubMed ID: 31337659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell Responses to
    Deniger DC; Pasetto A; Robbins PF; Gartner JJ; Prickett TD; Paria BC; Malekzadeh P; Jia L; Yossef R; Langhan MM; Wunderlich JR; Danforth DN; Somerville RPT; Rosenberg SA
    Clin Cancer Res; 2018 Nov; 24(22):5562-5573. PubMed ID: 29853601
    [No Abstract]   [Full Text] [Related]  

  • 6. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
    Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
    Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
    Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
    JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells.
    Kato T; Matsuda T; Ikeda Y; Park JH; Leisegang M; Yoshimura S; Hikichi T; Harada M; Zewde M; Sato S; Hasegawa K; Kiyotani K; Nakamura Y
    Oncotarget; 2018 Feb; 9(13):11009-11019. PubMed ID: 29541393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma.
    Ren L; Leisegang M; Deng B; Matsuda T; Kiyotani K; Kato T; Harada M; Park JH; Saloura V; Seiwert T; Vokes E; Agrawal N; Nakamura Y
    Oncoimmunology; 2019; 8(4):e1568813. PubMed ID: 30906664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
    Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
    J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.
    Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA
    Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
    Tate T; Matsumoto S; Nemoto K; Leisegang M; Nagayama S; Obama K; Nakamura Y; Kiyotani K
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of T cell receptor specifically reactive with autologous tumour cells from tumour-infiltrating lymphocytes and construction of T cell receptor engineered T cells for esophageal squamous cell carcinoma.
    Tan Q; Zhang C; Yang W; Liu Y; Heyilimu P; Feng D; Xing L; Ke Y; Lu Z
    J Immunother Cancer; 2019 Aug; 7(1):232. PubMed ID: 31462302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
    Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing.
    Lu YC; Zheng Z; Lowery FJ; Gartner JJ; Prickett TD; Robbins PF; Rosenberg SA
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.
    Zhao Q; Jiang Y; Xiang S; Kaboli PJ; Shen J; Zhao Y; Wu X; Du F; Li M; Cho CH; Li J; Wen Q; Liu T; Yi T; Xiao Z
    Front Immunol; 2021; 12():658753. PubMed ID: 33859650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.